COVID-19 Implications for Pharmaceutical Litigation

Share

Ceren Canal Aruoba of Cornerstone Research speaks to Darius Lakdawalla of the University of Southern California about the economics of pharmaceutical markets and the impacts of COVID-19 from the manufacturer perspective.

In particular, they discuss innovation and vaccine liability matters, and how pharmaceutical manufacturers might interact with other market stakeholders to address issues raised by COVID-19. In addition, Professor Lakdawalla describes common empirical errors in economic analyses performed for litigation, and the challenges brought on by COVID-19 in this process.

The podcast is available from the Speaking of Health Law channel of the American Health Law Association.


The views expressed in this podcast are solely those of the speakers, who are responsible for the content, and do not necessarily represent the views of Cornerstone Research.

COVID-19 Implications for Pharmaceutical Litigation

Speakers

Darius Lakdawalla

Quintiles Chair in Pharmaceutical Development and Regulatory Innovation,
Professor, School of Pharmacy,
Professor, Sol Price School of Public Policy,
Director of Research, Leonard D. Schaeffer Center for Health Policy and Economics,
University of Southern California

  • Washington

Ceren Canal Aruoba

Principal